Skip to main content

Table 2 Seropositivity rates for NMO-IgG and AQP4 autoantibodies in different groups of central nervous system idiopathic inflammatory demyelinating disorders, other neurological disorders, and healthy subjects.

From: Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays

Patient/control groups Number of subjects Number seropositive for NMO-IgG by tissue-based IIFA (%) Number seropositive for AQP4 autoantibody by cell-based IIFA (%) Significance
p value
NMO 18 11 (61%) 14 (78%) [3 +++, 3 ++, 8 +] ns
Relapsing myelitis 15 6 (40%) 9 (60%) [4 ++, 5 +] ns
Relapsing myelitis with LETM 12 6 (50%) 9 (75%) [4 ++, 5 +] ns
Single attack of acute myelitis 25 0 1 (4%) [+] ns
Single attack of LETM 2 0 1 [+] ns
Relapsing ON 9 2 (22%) 3 (33%) [2 ++, 1 +] ns
Single attack of ON 14 1 (7%) 2 (14%) [1 ++, 1 +] ns
Classical MS 40 0 0 ns
ADEM 7 0 0 ns
Healthy subjects 10 0 0 ns
Other neurological disorders 35 0 0 ns
  1. Abbreviations: NMO = neuromyelitis optica, LETM = longitudinally extensive transverse myelitis, ON = optic neuritis, MS = multiple sclerosis, ADEM = acute disseminated encephalomyelitis, IIFA = indirect immunofluorescence, AQP4 = aquaporin-4, +++ strongly positive, ++ positive, + weakly positive, ns = not significant.